Japanese automakers vulnerable to one-two punch of Iran war, yen rally
Japanese automakers are looking vulnerable to fallout from the Iran war and any turnaround in the yen.
Tuesday, 18 August 2026
Global markets, trading & world business — for professional traders
Japanese automakers are looking vulnerable to fallout from the Iran war and any turnaround in the yen.
No surprises on inflation and new financing developments in the artificial intelligence trade drove the record-breaking action on Wall Street last week.
Semiconductor stocks have made investors’ fortunes over the past four years, and by extension, semiconductor ETFs turned into the best-performing names. Names like the VanEck Semiconductor ETF (NASDAQ:SMH), Corgi Lithog…
Cisco shares dropped in extended trading on Wednesday despite a better-than-expected earnings report and a revenue forecast that sailed past estimates.
Experts view this transaction as a strategic win for both ExxonMobil and SBM Offshore, solidifying long-term control for ExxonMobil in Guyana's oil sector while allowing SBM to deleverage and monetize its assets effecti…
Investors shouldn't expect the bumper gains returned by the equity market so far this year to continue, the CEO of the world's largest sovereign wealth fund told CNBC on Wednesday.
Tencent posted a beat on second-quarter revenue thanks to an acceleration at its China gaming unit and AI-driven advertising, but its core profit missed analyst expectations.
We're lifting our price target on Cardinal Health after issuing rosy profit guidance The quarter wasn't totally clean, but strong profitability matters the most. Read at source
Global hotel giant IHG told CNBC a "growing middle class" is boosting travel demand, as it reported a boost in profits despite the Middle East conflict.
Here’s how we played the massive rebound in AI stocks this week AI stocks roared back to help lift two of the major averages to fresh records. Read at source
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806509750/en/
Peloton delivered its first full year of net profit and operating income in fiscal 2026, but said it expects sales to fall in the coming fiscal year as it begins to lap price increases on its hardware and subscription p…
Warner Bros. Discovery on Thursday said it saw record-breaking revenue growth in its streaming segment, anchored by HBO Max, ahead of increased scrutiny over its proposed merger with Paramount Skydance.
Restaurant Brands International on Thursday reported quarterly earnings that topped analysts' expectations, fueled by strong growth for the once-struggling Burger King, both domestically and abroad.
Gold is glittering, and it is time to make the most of it. While last year was a strong year for the precious metal, and has started 2026 even stronger. And after a recent pullback, prices have recovered with the market…
Rheinmetall on Thursday trimmed its 2026 guidance after a cancelled project to make large warships for the German government fell through earlier this year.
E.l.f. Beauty's profits nearly doubled during its fiscal first quarter thanks to a windfall of cash it received in tariff refunds from the federal government, the company said Wednesday.
Disney parks are defying a slump in international travel to the U.S., posting record quarterly revenue for the company's experiences division on Wednesday.
The strength of its GLP-1 business suggests the stock still has more room to run.
Disney reported growth at its domestic theme parks and cruises despite mounting macroeconomic uncertainty for consumers.
CVS also announced a new collaboration with Eli Lilly that will make Zepbound and Foundayo accessible to eligible patients on the CVS Health app.
Eli Lilly on Wednesday reported second-quarter earnings and revenue that blew past estimates and hiked its full-year sales outlook, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro…
The market thrilled with SpaceX's first-ever earnings report — but big slide on Wednesday might be a buy-the-dip opportunity for investors based on what Wall Street analysts are saying about their outlook.
Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.